mined by BLI measurements. (C) Pie chart summarizing antibody binding profiles. Cross-reactive mAbs refer to those that bind to both GP and sGP. N.B., nonbinder; W.B., weak binder. IgG equilibrium dissociation constants were calculated for mAbs with BLI responses >0.1 nm. MAbs with BLI responses <0.05 nm were designated as N.B.s; MAbs with BLI responses between 0.05 and 0.1 nm were designated as W.B.s. All data are representative of two or more independent experiments.
after the empathy induction and in selfish types [motive induction × individual type, F(1,30) = 4.9, P = 0.034] (Fig. 4C) .
Motives are purely mental constructs that are not directly observable. Here we show, however, that distinct motives have a distinct neurophysiological representation in the brain. Although the empathy and the reciprocity motive increase the frequency of altruistic acts by the same amount relative to the baseline condition, they are associated with different patterns of brain connectivity that enabled us to predict the different motives with relatively high accuracy. We predicted each subject's induced motive with a classifier whose parameters were not influenced by that subject's brain data (nor by that subject's behavioral data). Instead, the parameters of the classifier were solely informed by other subjects' brain data. This means that the motive-specific brain connectivity patterns are generalizable across subjects. The distinct and across-subject-generalizable neural representation of the different motives thus provides evidence for a distinct neurophysiological existence of motives.
The findings also provide mechanistic insights into the neural underpinnings of important altruistic motives and how motive inductions change the underlying neural network. In particular, predominantly selfish individuals were characterized by a low or even negative connectivity from ACC→AI in the baseline condition, whereas predominantly prosocial individuals displayed a positive connectivity between these regions. However, when we induce the empathy motive, the selfish, but not the prosocial, types become more altruistic and show a substantial increase in ACC→AI connectivity. Thus, after the empathy induction, selfish individuals resemble "homegrown" unconditional altruists in terms of both brain connectivity and altruistic behavior. This contrasts with the effect of inducing the reciprocity motive, which renders the prosocial, but not the selfish, types more altruistic and increases only the prosocial types' AI→VS connectivity.
We obtain these mechanistic insights because the inputs into the support vector machine are not merely brain activations but small brain models of how relevant brain regions interact with each other (i.e., functional neural architectures). Thus, by correctly predicting the induced motives, we simultaneously determine those mechanistic models of brain interaction that best predict the motives. And it is these models that deliver the mechanistic insights into brain function and how changes in brain function relate to behavioral changes due to motive inductions. Our study, therefore, also demonstrates how "mere prediction" and "insights into the mechanisms" that underlie psychological concepts (such as motives) can be simultaneously achieved if functional neural architectures are the inputs for the prediction.
decisions in the motive-induction conditions, the behavioral classification becomes marginally significant (classification accuracy of 64.2%, P = 0.051). However, if we perform the same classification analysis with connectivity data-i.e., in addition to the ∆-DCM parameters we also use the level of the DCM parameters in the baseline condition for classification purposes-the classification accuracy increases even to 83%, P = 0.00004. Thus, the classification based on brain connectivity data clearly outperforms the behavior-based classification (see also supplementary materials). 30 trimer is the sole known target for protective antibodies and is currently the primary target for antiviral vaccines and therapies (2, 3) . A small number of protective monoclonal antibodies (mAbs) to GP have been isolated from immunized mice, and recent structures of these antibodies in complex with GP have illuminated key sites of vulnerability on the EBOV glycoprotein (3-7). However, only a small number of mAbs to GP have been isolated from human EBOV survivors (8) (9) (10) , and therefore the characteristics of the human antibody response to EBOV GP remain largely undefined. In this study, we aimed to comprehensively profile the human B cell response to EBOV GP by cloning an extensive panel of mAbs to GP from the peripheral B cells of a convalescent donor (subject 45) who survived the 2014 EBOV Zaire outbreak. Three months after primary infection, the donor plasma showed strong immunoglobulin G (IgG) binding reactivity to EBOV GP and potent neutralizing activity, suggesting that this donor had mounted a robust neutralizing antibody (Nab) response to GP by this time point (fig. S1, A and B). To assess the magnitude of the B cell response to EBOV GP, B cells were stained with a fluorescently labeled EBOV GP ectodomain (GPDTM) (4) and analyzed by flow cytometry. Approximately 3% of IgG + B cells were specific for GPDTM ( fig. S2 ), which is comparable to the percentage of circulating antigen-specific peripheral B cells observed during chronic HIV infection and after primary dengue infection (11, 12) . Cognate antibody heavy-and light-chain pairs were rescued from 420 individual GPDTM-reactive B cells by single-cell polymerase chain reaction and were subsequently cloned and expressed as full-length IgGs in an engineered strain of Saccharomyces cerevisiae (13) . Of the 420 cloned mAbs, 349 bound to EBOV GP in preliminary binding screens (table S1). Analysis of the heavyand light-chain variable regions (V H and Vk, respectively) revealed that the anti-GP repertoire was highly diverse, containing 294 independent clonal lineages ( fig. S3A and table S2 ). This result contrasts with previously described anti-HIV and anti-influenza repertoires, which show a significantly higher degree of clonal restriction (11, 14) .
Comparison to non-GP-reactive antibodies (15) revealed that the EBOV GP-specific repertoire was skewed toward Ig light-chain kappa (Igk) versus Ig light-chain lambda (Igl) and longer heavychain complementarity-determining region 3 (CDRH3) lengths ( fig. S3 , B and C, and table S2). Similar biases have also been observed in HIV-1-infected patient repertoires (11, 12) . V H and Vk germline gene usage in the GP-specific repertoire was similar to non-GP-specific repertoires ( To map the antigenic specificities of the mAbs to GP, we produced 321 IgGs in larger quantities and performed biolayer interferometry (BLI) binding experiments with several GP variants. We first tested binding to EBOV GPDTM and a mucin-like domain deletion construct (GPDmuc) (6) . Unexpectedly, only two mAbs failed to bind to GPDmuc, indicating that less than 1% of the GP-specific antibody response in this donor is directed against epitopes within or dependent on the mucin-like domain ( Fig. 1A and table S3 ). About 30% of the mAbs showed increased binding responses and faster association rates to GPDmuc as compared to GPDTM ( fig. S4 ), suggesting that these mAbs probably recognize epitopes that are partially occluded by the mucin-like domain. We next tested the mAbs for binding to a secreted GP isoform, sGP, which is expressed as a disulfide-linked GP1 dimer containing the majority of the mucin-like domain-free GP1 core and glycan cap sequence ( fig. S5) (17, 18) . This analysis revealed that 39% of GPDmuc-reactive mAbs failed to bind to sGP, 2% bound with similar apparent affinity to both GPDmuc and sGP, and 59% reacted with both proteins but bound with higher apparent affinity to sGP (Fig. 1, B and C, and table S3 ). The latter result is consistent with previous studies showing that sGP is secreted in large quantities during natural infection and may behave as an antigenic decoy by redirecting the immune response toward epitopes that are either inaccessible on surface GP or shared between the two proteins (17, 19) .
To further define the epitopes targeted by the mAbs to GP, we performed competitive binding experiments (20) . We first tested the 321 mAbs for competition with two well-characterized murine mAbs, 1H3 and 13C6, that recognize overlapping epitopes in the glycan cap (4). The vast majority of sGP cross-reactive binders competed with one or both mAbs, suggesting that they also bind within the glycan cap ( Fig. 2A and fig. S6A ). We next tested the GP-specific mAbs for competition with KZ52, a human antibody that binds at the interface of GP1 and GP2 (6, 8) . Approximately half of the GP-specific binders competed with KZ52 ( Fig.  2A and fig. S6B ), suggesting that this antigenic site is a common target for antibodies elicited by natural EBOV infection, at least for the donor studied. Because KZ52 has been shown to exhibit specificity for Zaire GP (6), we next tested selected KZ52 competitors for cross-reactivity with Sudan (SUDV) GP and Bundibugyo (BDBV) GP. Similar to KZ52, most of these mAbs did not show broad species cross-reactivity ( Fig. 2B and  fig. S7A ). However, in contrast to KZ52 and other well-characterized GP base binders (4), most of the KZ52 competitor mAbs failed to react with a minimal thermolysin-processed GP core, in which both the mucin domain and glycan cap regions had been proteolytically removed (GP CL ) (4) (Fig.  2C) . Thus, this class of antibodies appears to target specific epitopes that either directly overlap with the KZ52 epitope or are sterically inhibited SCIENCE sciencemag.org by the KZ52 Fab. To estimate the number of different antigenic sites recognized by the remaining GP-specific mAbs, we performed competitive binding experiments with four high-affinity mAbs from the panel (ADI-15974, ADI-15933, ADI-15810, and ADI-15983) that did not show significant competition with KZ52 or with each other (table  S4) . Eighty percent of the non-KZ52-competitive GP-specific mAbs bound to epitopes overlapping that of ADI-15974 or ADI-15810 ( Fig. 2A and fig.  S6B ). This group of mAbs also showed significantly broader cross-species GP-binding reactivity than the KZ52 competitors (Fig. 2D and fig.  S7B ). Overall, these data show that the anti-GP repertoire in this patient is primarily composed of clones that target four non-overlapping antigenic sites on EBOV GP (Fig. 2E) .
We next measured the neutralizing activity of the B cell-derived mAbs using a live virus plaque reduction neutralization (PRNT) assay. Because of the large number of mAbs and the high-throughput nature of our study, initial neutralization screening was performed using a single concentration of purified IgG (table S5 and fig. S9 ). Remarkably, 77 and 63% of the mAbs reduced viral infectivity by 50 and 80% (PRNT 50 and PRNT 80 ), respectively, at concentrations ≤50 mg/ml (Fig. 3A  and table S5 ). Control experiments with yeastproduced and CHO-produced (CHO, Chinese hamster ovary cells) IgGs demonstrated that functional activity is probably not affected by the host production system ( fig. S8 ). Analysis of neutralizing activity by a competition group revealed that the majority of competition groups contained a proportion of NAbs, with the KZ52 and 13C6/1H3 competition groups containing the highest proportion of NAbs (Fig. 3A and table S5 ). The latter result was unexpected, because 13C6 and 1H3 only weakly neutralize in the absence of complement (7, 21) . We next performed neutralization titration experiments in order to evaluate neutralization potency. These results showed that several NAbs, particularly those in the ADI-15974 and KZ52 competition groups, exhibited extraordinary potency. Half of the NAbs tested from the ADI-15974 competition group, and two of the NAbs tested from the KZ52 competition group, neutralized with PRNT 50 values ≤0.05 mg/ml (Fig.  3B and table S5 ). In contrast, the majority of 13C6 and/or 1H3 competitor mAbs neutralized with relatively modest potency, with PRNT 50 values averaging 3.3 mg/ml. We conclude that the GPspecific antibody repertoire in the donor studied contains a high proportion of NAbs, the most potent of which bind to epitopes overlapping those of KZ52 or ADI-15974.
To structurally define the epitopes recognized by the NAbs, we used single-particle electron microscopy (EM) to examine five potent NAbs, representing each of the four major competition groups, in complex with fully glycosylated EBOV GPDTM. These NAbs included ADI-15731 (a 13C6 competitor), ADI-15734 and ADI-15762 (KZ52 competitors), ADI-15758 (an ADI-15974 competitor), and ADI-15859 (an ADI-15810 competitor). We were able to obtain negative-stain two-dimensional (2D) class averages for all five complexes of Fabs bound to EBOV GPDTM ( fig. S10 ) and 3D reconstructions for four of the Fab:EBOV GPDTM complexes at 18 to 24 Å resolution (Fig. 4 and fig. S11 ). In agreement with the competitive binding data, the EM reconstruction of ADI-15731 showed that this NAb binds within the glycan cap, with a footprint approximately between the epitopes recognized by 13C6 and 1H3 and with a similar angle of approach (Fig. 4 and fig. S12A ). We next examined the two KZ52 competing NAbs, ADI-15734 and ADI-15762. As anticipated, ADI-15734 bound to EBOV GPDTM at the GP1/GP2 interface, slightly adjacent to the KZ52 epitope and at a similar angle of approach (Fig. 4 and fig. S12C ). In contrast, ADI-15762 actually binds within the glycan cap, but with a shallow binding angle that probably sterically occludes the KZ52 epitope (Fig. 4  and fig. S12B ). Last, we determined the structure of EBOV GPDTM in complex with ADI-15758 (an ADI-15974 competitor), one of the most potent NAbs described in this panel. The EM reconstruction shows that ADI-15758 binds to a region proximal to the viral membrane, distal to all previously described epitopes, and below the body of the trimeric EBOV GP structure (Fig. 4 and fig. S12D ). Although this region has not yet been structurally characterized at high resolution in the pre-fusion GP context, it corresponds to the a-helical heptad repeat 2 (HR2; residues 613 to 637) defined in the post-fusion conformation (22) . Docking of the EBOV GP crystal structure into the reconstruction suggests that the ADI-15758 epitope is within the C-terminal 24 residues of GP2 contained in the EBOV GPDTM construct (6) . Three Fab molecules SCIENCE sciencemag.org (5) surface representation of the EBOV GP trimer. The mucin domain (gray), glycan cap domain of GP1 (aqua green), GP1 core (blue), GP2 (light blue), fusion loop region of GP2 (pink), and the stalk/HR2 region (orange) have been mapped onto the structure. The residues that make up the trimeric body and the stalk region of the EBOV GP are displayed on the left. The mucin domains are modeled only as spheres, because they are largely unstructured and poorly defined (27) . Residues 613 to 637 corresponding to the stalk/HR2 region were modeled in silico using threefold symmetry and peptide structure prediction for the HR2 region (28) . (B) Corresponding 3D reconstructions of four Fab:EBOV GPDTM complexes are shown in transparent surface representation (gray) with the model from (A) fitted in the density. Additionally, structural models for each Fab variable region were generated using the ROSIE server (29, 30) and then fitted into the density maps as surface representations. Each structure is shown as side (left) and top (right) views, with the exception of ADI-15758, which is shown from the bottom up, respective to the viral membrane.
could be visualized in the 2D class averages ( fig.  S10 ), suggesting that the HR2 region may exist as a three-helix bundle in the pre-fusion GP structure (6) . Additionally, although we were not able to generate a 3D reconstruction of ADI-15859 (an ADI-15810 competitor) bound to EBOV GPDTM, the negative-stain 2D class averages indicate that this mAb also binds within the GP stalk region. Collectively, these data suggest that the GP stalk region containing the HR2 helices is an accessible antigenic region targeted by NAbs, a proportion of which exhibit remarkable neutralization potency.
Finally, we sought to determine whether certain NAbs to GP showed greater in vivo efficacy than others. For this experiment, several NAbs were selected from each competition group and evaluated for post-exposure therapeutic efficacy against lethal EBOV challenge in a murine infection model (23) . Groups of mice were challenged with a target dose of 100 plaque-forming units (PFU) of mouse-adapted EBOV (MA-EBOV), followed by a single 100 mg dose of mAb at 2 days post-infection (dpi). The previously described neutralizing mAb 2G4, a component of the ZMapp cocktail, was also included for comparison (3) . Of significance, all of the ADI-15974 competitor NAbs (GP stalk binders) provided significant postexposure protection, with survival rates ranging from 60 to 100% and average weight loss ranging between 8 and 10% (Fig. 5A, fig. S13 , and table S6). Five out of the six NAbs in the KZ52 competition group were also highly effective in protection, with survival rates ranging between 60 and 100% ( Fig. 5B and table S6 ). With the exception of ADI-15818 (a KZ52 competitor), all of the NAbs in these two competition groups showed greater therapeutic efficacy than 2G4, which only provided 40% protection under these conditions. In contrast to the ADI-15974 and KZ52 competitor NAbs, the NAbs targeting the glycan cap (13C6/1H3 competitors) and undefined epitopes generally showed little to no therapeutic efficacy (Fig. 5, C and D, fig. S13 , and table S6). Only ADI-16037 (a 13C6 competitor NAb) provided potent protection, yielding 80% survival and 7% average weight loss. The remaining NAbs in these groups yielded ≤50% survival, which in most cases was not a statistically significant increase in protection over the negative control (Fig. 5, C and D, and  table S6 ). This result is consistent with previous studies showing that mAbs targeting the glycan cap generally do not afford significant protection when administered at 1 to 2 dpi (3, 24) . In summary, most of the NAbs targeting the GP stalk region (ADI-15974 competitors) and the GP1/GP2 interface (KZ52 competitors) provided significant post-exposure protection against lethal EBOV challenge, whereas NAbs targeting the glycan cap (13C6/1H3 competitors) and undefined regions generally showed little to no therapeutic efficacy under these conditions.
We have shown that the human B cell response to EBOV GP is composed of a broad diversity of clones that primarily target three non-overlapping antigenic sites on the GP spike: the glycan cap; the GP1/GP2 interface; and the stalk , inclusive of the HR2 helices ( fig. S14) . A substantial fraction of the mAbs cloned from GP-specific B cells show neutralizing activity, demonstrating that at least in this donor, NAb responses can develop relatively early after EBOV infection. The most potently neutralizing and therapeutically effective mAbs in our panel target the GP1/GP2 interface and the GP stalk region, suggesting that these epitopes may be promising targets for rational vaccine design. In addition, the observation that EBOV escape variants can emerge after treatment with the MB-003 antibody cocktail highlights the need for protective mAbs that target new antigenic sites, such as those described here targeting the GP stalk (25, 26) .
